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ABSTRACT 
Objective: The goal of this study was to identify in human 
immunodeficiency virus (HIV)-infected individuals immunologic 
markers that correlated with transmission of HIV by hetero- 
sexual contact. 
Methods: In a case-control comparison of couples, immuno- 
logic and viral parameters were evaluated in 343 HIV-positive 
individuals who were members of 67 HIV-seroconcordant cou- 
ples (both partners HIV positive) and 21 I HIV serodiscordant 
couples (one positive, one negative). 
Results: The most striking immunologic finding was the 
increased numbers of CD3+CD8+ cells found in the index 
member of discordant couples as compared to the index mem- 
ber of the concordant couples. Differences in CD3+CD8+ lev- 
els persisted after adjustment for stage of disease and 
CD3+CD4+ count. This increase in the number of CD3+CD8+ 
cells was accompanied by a concomitant decrease in the 
amount of viral replication measured by both HIV culture end- 
point and quantitative RNA polymerase chain reaction (PCR). 
Conclusion: Data presented here further support the role of 
CD3+CD8+ cells in suppressing or controlling viral activity, 
although a causal role based on case-control data must be 
advanced cautiously. This in vivo biologic function may help 
prevent or lower the risk of HIV transmission. 
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The principal worldwide mode of human immunodefi- 
ciency virus (HIV) transmission is heterosexual inter- 
course. In cross-sectional or longitudinal studies 
performed to evaluate factors related to heterosexual HIV 
transmission, the major risk factors identified have been 
sexual practices and the presence of ulcerative or non- 
ulcerative sexually transmitted diseases.‘-’ Recent studies 
have focused on the potential role of histocompatibility 
patterns and CD4 susceptibility via chemokine receptor 
expression.8x9 In some instances HIV transmission has 
occurred despite a low number of sexual contacts. In 
others, no transmission has occurred despite high num- 
bers of contactslo 
There is limited information on biologic factors that 
could promote or retard transmission. Such factors would 
include immunologic status of the HIV-positive or the 
HIV-negative partner, viral burden, and characteristics of 
the HIV strains. Beginning in August 1990, the authors 
enrolled heterosexual couples who were serodiscordant 
for HIV-l infection into a prospective study of infection 
by heterosexual transmission. Couples in stable partner- 
ships were eligible if the uninfected partner was at risk 
of infection solely through sexual contact with the HIV- 
positive partner (by definition, the primary partner). Cou- 
ples were scheduled for follow-up every 6 months 
through June 1993. Due to low seroconversion, a com- 
parison group of couples concordant for HIV seroposi- 
tivity was added in February 1992. Concordant couples 
were eligible if there was evidence that one partner was 
infected by sexual contact with the other, defined as the 
primary partner. 
As part of the longitudinal follow-up a comprehen- 
sive laboratory assessment was conducted, and this report 
presents the immunologic and retrovirologic laboratory 
data obtained at enrollment. Laboratory data are pre- 
sented for the HIV-infected members of discordant cou- 
ples and compared to patterns observed for members of 
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HIV-concordant couples. Data on demographdc, behav- 
ioral, and genetic factors are being reported separately.” 
MATERIAL AND METHODS 
The protocol was reviewed and approved by the Insti- 
tutional Review Board and informed consent was 
obtained from all participants. 
Subjects 
Data were obtained from 363 HIV-positive individuals 
who were members of 77 HIV-positive concordant cou- 
ples (both partners HIV-positive) and 2 11 HIV-discordant 
couples. The racial or ethnic composition of discordant 
couples was 28% Hispanic, 22% black non-Hispanic, 46% 
white non-Hispanic, and 3% other; partners in concor- 
dant couples were 43% Hispanic, 36% black non-Hispanic, 
18% white non-Hispanic, and 3% other. Mean age of male 
partners was 36 years (range, 21-68 y); mean age of 
females was 33 years (range, 18-60 y). All HIV-positive 
members of couples were reactive on both enzyme-linked 
immunosorbent assay (ELISA) and Western blot; all HIV- 
seronegatives were nonreactive on both ELISA and West- 
ern blot and on polymerase chain reaction (PCIR) testing. 
Eligibility was restricted to couples whose second- 
infected partner had never used injection drugs, was not 
a homosexual male, did not have contact with any other 
partner suspected of being HIV positive, and had not 
received HIV-tainted blood products. Each individual was 
examined for track marks by a physician, and urine sam- 
ples were screened for opiates and cocaine. In 10 con- 
cordant couples it was unclear who was the primary 
partner; these have been excluded from the analyses. 
Laboratory Methods 
HIV Culture Isolation 
Standard cultures for HIV were performed following the 
National Institute of Allergy and Infectious Diseases 
(NIAID) AIDS Clinical Trials Group (ACTG) Virology Lab- 
oratory Manual. Additional cultures of HIV-seropositive 
study participants were performed using a quantitative 
endpoint microculture technique as a viral burdlen assess- 
ment.12x13 Recovered isolates and cells from cultures were 
cryopreserved in liquid nitrogen with the aid of a con- 
trolled-rate freezing device (Cryomed, New Eialtimore, 
MD). Recovered HIV isolates were screened for syn- 
cytium-inducing characteristics using MT-2 cells. l2 
HIVp24 Antigen Determination 
Human immunodeticiency virus p24 antigen was deter- 
mined on serum samples, using a commercial sa:ndwiched 
based polyclonal (EL4) (HIVAG-1, Abbott Laboratories, 
Abbott Park, IL). Quantitation was obtained by compar- 
ing the optical density of the sample to a calibration curve. 
Standards for establishing the calibration curve were pro- 
vided by the ACTG Virology Reference Laboratory.l’ 
HNRXA Quantitation 
Blood specimens were collected in heparin and 
processed within 6 hours. Plasma was cryopreserved and 
stored at -70°C. The nucleic acid sequence-based ampli- 
fication (NASBA) (Organon Teknika, Durham, NC) assay 
was used to quantitate plasma RNA; RNA was extracted 
from 100 FL of plasma. Amplification and detection were 
performed according to the manufacturer’s protocol. Final 
quantification was adjusted to reflect RNA copies per 
milliliter of plasma. 
Detection of HIV 2 p24 and 
HIP-I gp160 Antibodies in Serum 
Antibodies to HIV-l p24 were measured using an ELISA 
in a semiquantitative format (Advanced Bioscience Lab- 
oratories, Kensington, MD). Test sera were assayed in 
duplicate at l:lOO, l:lOOO, and l:lO,OOO dilutions. Anti- 
bodies to HIV-l gpl60 were measured using an ELISA 
that used purified native gpI60. The assay was performed 
similarly to that described above for antibodies to HlV-1 
p24 (Advanced Bioscience Laboratories). 14*15 
Flow Cytometric Immunopbenotyping 
Lymphocyte subsets were determined using standard 
flow cytometric techniques for simultaneous, direct, two- 
color immunofluorescence staining of whole blood.16 
The same sample of blood used to determine lympho- 
cyte subsets was also used to determine the total and dif- 
ferential leukocyte counts, using a Sysmex E-2500 
electronic cell counter (TOA Medical Electronics, Kobe, 
Japan). The absolute numbers of cells for each lympho- 
cyte subset were calculated by multiplying the corrected 
relative value by the total lymphocyte count. 
Analytic and Statistical Methods 
Human immunodeficiency virus-concordant partners 
were classified by status as primary or secondary case 
within the couples, based on risk-exposure history of 
each partner and time of first HIV-seropositive test. 
Human immunodeficiency virus-positive members of dis- 
cordant couples constituted the primary partners, and 
HIV-negative partners were secondary partners. Statisti- 
cal analyses were directed at (1) estimating the degree of 
association between cell subset counts and viral load; 
and (2) distinguishing between concordant and discor- 
dant couples by comparison of primary concordant and 
primary discordant partners. Lymphocyte immunopheno- 
typing was analyzed to characterize the cohort by rela- 
tive and absolute counts of CD3+, CD3+CD4+, 
CD3+CDS+, CD19+, and natural killer cells (CD16+ and 
188 International Journal of Infectious Diseases / Volume 2, Number 4, April-June 1998 
CD57+). Virology data (quantitative standard p24 antigen 
and culture endpoint dilution assay, RNA copies, and anti- 
bodies to p24 and gpl60 viral proteins) were analyzed for 
proportion of HIV-positive individuals positive on assay 
and for distribution of viral load levels. Analysis of vari- 
ance was used to compare the means of variables with 
approximately normal distributions (e.g., age). Rank sum 
tests and Spearman’s correlation coefficient were used 
for analyses of abnormally distributed cell subset counts 
and viral load measures. 
Multiple logistic regression models were developed 
to evaluate the joint impact of immunologic and viro- 
logic measures on concordant status of couples. RNA 
copy numbers below the detection limit of 1000 were 
imputed a value of 500 for logistic regression. 
RESULTS 
Subjects 
Table 1 summarizes cohort characteristics for each patient 
group by gender, mode of infection, clinical stage of dis- 
ease, history of antiviral medications, and time since first 
HIV-positive antibody test to study enrollment. Patient 
characteristics are presented for each patient group stud- 
ied: primary concordant (PC); primary discordant (PD); 
secondary concordant (SC); and unknown concordant 
(UC). Significantly more primary concordant partners 
were on antiviral therapy compared to primary discordant 
partners (I? = 0.003). The elapsed time from the initial 
Table 1. Characteristics of Patients in Each Study Group 
Primary Primary Secondary 
Concordant Discordant Concordant 
Patient Characteristics n = 67 n=211 n = 65 
Gender 
Male 57 (85%) 159 (75%) 10 (15%) 
Female 10 (15%) 52 (25%) 55 (85%) 
Data available n = 67 n=211 n = 65 
Mode of infection 
IDU 49 (73%) 131 (62%) 0 
Heterosexual contact 15 (22%) 51 (24%) 58 (90%) 
Male-with-male 2 (3%) 6 (3%) 0 
HIV + blood 0 1 (0%) 
Other 1 (1%) 22 (10%) 7 (h%) 
Data available n = 67 n=211 n = 65 
Stage of disease 
Asymptomatic 23 (35%) 122 (58%) 46 (71%) 
Symptomatic 16 (24%) 26 (12%) 8 (12%) 
AIDS 27 (41%) 61 (29%) 11 (17%) 
Data available n = 66 n = 209 n = 65 
Antiviral therapy 
Current prescription 42 (70%)+ 88 (47%) 29 (54%) 
Data available n = 60 n=186 n = 54 
HIV-seropositive time*5 
Median 30 12 16 
25th percentile 11 3 6 
75th percentile 48 33 32 
P = value for comparison of PC to PD; *0.005; +0.003; *0.0002; smonths since 
first positive test to enrollment. 
Table 2. Absolute Distribution of Immune Cells of Each 
lmmunophenotype by HIV-Positive Subject Category 
Primary Primary Secondary 
Discordant Concordant Concordant 
Phenotype n=271 n = 64 n = 65 
CD3+/mm3 
Mean t SD 1569 ? 794 1039 ? 655 1465 ? 676 
Median 1510 985 1358 
CD3+CD4+/mm3* 
Mean i SD 443 + 333 269 -t 256 440 i 295 
Median 399 240 421 
CD3+CD8+/mm3* 
Mean k SD 1158 i- 627 742 I 456 992 + 507 
Median 1091 693 862 
CD1 9+/mm3 
Mean k SD 225 ? 140 183 t 120 228 t 121 
Median 207 151 207 
CD1 6+CD56++ 
Mean IT SD 153 2 115 133 k 108 141 2 88 
Median 129 90 109 
n = 68 n = 61 n = 62 
*For PC to PD comparison by Wilcoxon’s rank sum tests, P = 0.0001. 
+Data not available for full cohort as monoclonal antibody panel was modified 
during study to include markers for natural killer cells. 
seropositive test was longer for the PC compared to 
the PD group (median, 30 months vs. 12 months, 
P < 0.0002). 
Immunophenotyping 
Mean, plus or minus standard deviation (SD), and median 
for absolute values of each immunophenotype studied 
are summarized in Table 2. The difference in CD3+CD8+ 
cells between discordant and concordant primary part- 
ners was striking. Discordant HIV-positive partners had 
a median CD3+CDS+ count of 1091/mm3 compared to 
693/mm3 for the concordant primaries, a 57% higher 
count in discordants. When immunophenotypic para- 
meters were adjusted for time since first positive HIV 
test, the mean differences between the two study groups 
remained significant for relative and absolute CD3+, 
CD3+CD4+, and CD3+CDS+ cells. 
Because CD3+CD4+ differences were observed 
between the two study groups (i.e., PD and PC) the 
means of CD3+CDS+ absolute values were adjusted for 
the CD3+CD4+ level. The PD CD3+CD8+ absolute mean 
count remained significantly higher than the mean for 
PC group. Thus, differences in the CD3+CD4+ level did 
not account for the differences observed in the 
CD3+CD8+ subset. 
Based on the laboratory’s reference range (mean, 605 
2 292) for the absolute T-suppressor cell (CD3+CD8+) 
subset, values were arbitrarily categorized as normal 
(<1200),moderatelyhigh(1200-1599),high(1600-1999), 
and very high (22000) as shown in Figure 1. Among 64 
PC individuals, only one (2%) had a count at the high 
level and none at the very high level. In contrast, of the 
211 PD individuals, 18 (9%) had a high level and 26 (12%) 




" <1200 1600-1999 
1200-1595 >2000 
cells I mm3 
Primary Discordant 






cells I mm3 
Figure 1. Index case categorization by absolute T-suppressor cell 
number. Distribution of primary concordant or primary discordant 
patients by CD3+CD8+ cell-count levels. For the primary discordant 
group, an increased number of patients show CD3+CD8+ levels in the 
over 1 600/mm3 category. 
showed very high levels of T suppressor cells. The dif- 
ference in proportions of normal, moderately high, high, 
and very high values is significant, after stratification for 
stage of disease levels (P = 0.001). 
HIV Endpoint Culture and Isolate Phenotyping 
To provide another measure of viral burden and to per- 
mit an assessment of whether virus characteristics 
accounted for transmission and nontransmission, HIV end- 
point cultures were added midway through the study and 
thus are available on only 131 HIV-positive patients. Of 
the 131 patients, 96 (73%) demonstrated a positive cul- 
ture with a 207 t 711 (mean ? SD) infectious units per 
million (IUPM) cells: 79% of PC subjects showed viral 
growth compared to 57% of PD subjects (Table 3). A neg- 
ative correlation (r, = -.20, P = 0.020) existed between 
the absolute CD3+CD4+ level and the endpoint culture 
IUPM value (Table 4). Among those who did and did not 
grow virus, absolute CD3+CD4+ values were similar 
(mean, 348 and 408 cells/FL, respectively). Absolute 
CD3+CDS+ counts were also negatively correlated with 
endpoint dilution IUPM values (r, = -.28, P = 0.0015). 
The levels were substantially higher in PC compared to 
PD partners (rank sum test P = 0.03). 
Sixty-six viral isolates were phenotyped to determine 
frequency of syncytium formation (thought to be an indi- 
cator of greater strain virulence). Syncytium induction 
(SI phenotype) was present in 61% (40/66) of isolates. 
The proportion of SI was the same for PD and PC part- 
ners (58% vs. 59%, respectively). The proportion among 
secondary partners was slightly higher (SI = 73%). How- 
ever, the sample size was small (n = 15). No correlation 
of SI distribution was noted with respect to IUPM val- 
ues, p24 antigen levels, or absolute number of CD3+CD4+ 
Table 3. Virology Laboratory Parameters 
Primary Primary Secondary 
Virology Concordant Discordant Concordant 
Measurement n = 67 n=211 n = 65 P Value* 
RNA copies/ml 
Median 93,000 25,000 
25th percentile 20,000 2,200 Not done 0.0002 
75th percentile 460,000 110,000 
Positive (%) 53/60 105/i 35 
(88%) (78%) 
Endpoint HIV Culture+ 
Median 3.2 0.5 5.4 
25th percentile 0.4 0.0 0.3 0.03 
75th percentile 82.0 14.0 41 .o 
Positive (%) 34/43 20/35 32/41 
(79%) (57%) (78%) 
HIV p24 antibody* 
Median 2,030 2,935 
25th percentile 208 418 Not done 0.12 
75th percentile 12,750 37,003 
HIV gpl60 antibody* 
Median 138,900 162,300 
25th percentile 71,700 95,500 Not done 0.26 
75th percentile 229,000 247,000 
*Significance level of Wilcoxon’s rank sum test for comparison of discordant 
and concordant primary partners. 
iNumber infectious units/million mononuclear cells. 
*Reciprocal value of titer. 
or CD3+CD8+ cells. Thus, there was no evidence on this 
analysis that viral strain variations accounted for different 
transmission proclivity. 
HIV RNA Quantitation 
Human immunodeficiency virus plasma RNA levels were 
available for 195 HIV-positive primary partners (PC, n = 
60, and PD, n = 135). Detectable RNA was present in 158 
(81%) (see Table 3). After imputing 500 for samples with 
undetectable virus, the log,, copy number was 4.41 
+ 1.08 (mean + SD). The median copy value was 35,000 
with a maximum of 6.6 X 106. RNA copy number was 
negatively correlated (see Table 4) with absolute 
CD3+CD4+ (rS = -.51, P = 0.0001) and CD3+CD8+ 
(r, = -.36, P = 0.0001) numbers. The number of RNA 
copies and p24 antibody were also negatively correlated 
(r, = -.25, P = 0.0006). RNA copies were significantly 
higher in the PC compared to the PD group. Median val- 
ues were 93,000 versus 25,000 with a rank sum test value 
of P = 0.0002. The proportion of patients with detectable 
RNA was 88% in the concordant, and 78% in the discor- 
dant category 
HIV ~24 and gpl60 Antibody 
Human immunodeficiency virus p24 antibody results 
were obtained on 255 HIV-positive primary partners (PC, 
n = 62, and PD, n = 193); all showed p24 antibody. The 
median value was 1:2119, with a minimum titer of 1:28 
and a maximum titer of 1:13,600,000. A positive Spear- 
man’s correlation (rS = .31, P = 0.0001) was found 














Table 4. Correlation of Viral Load and immune Measures* 
Endpoint 
H/V Culture 
CD3+CD8+ RNA (W/M mono- HIV p24 HIV Gp 160 
(cells/mm3) (copies/mL) nuclear cells) AB titer AB titer 
0.52 -0.51 -0.20 0.31 0.26 
(0.0001, n = 360) (0.0001, n = 192) (0.020, n = 130) (0.0001, n = 253) (0.0001, n = 253) 
-0.36 -0.28 0.19 0.30 
(0.0001, n = 192) (0.0015, n = 130) (0.003, n = 253) (0.0001, n = 253) 
0.29 -0.25 -0.08 
(0.019, n = 66) (0.0006, n = 191) (0.28, n = 191) 
-0.25 -0.17 
(0.031, n = 74) (0.16, n = 74) 
0.44 
(0.0001, n = 255) 
Spearman correlation coefficient (P = value, n). 
IU/M = infectious units/million. 
between absolute CD3+CD4+ levels and p24 antibody 
titers (see Table 4). Absolute CD3+CDS+ counts also 
showed a positive correlation (r, = .19, P = 0.003) with 
p24 antibody titers (see Table 4). When the correlation 
with absolute CD3+CD8+ counts was adjusted for 
absolute CD3+CD4+ levels, no association existed 
between p24 antibody titers and CD3+CD8+ numbers. 
Human immunodeficiency virus gpl60 antibody 
results were obtained on 255 HIV-positive primary part- 
ners (PC, n = 62, and PD, n = 193); all showed gpl60 
antibody. The median value was 1:154,000 with a mini- 
mum of 1:5500 and a maximum titer of 1:1,123,000. No 
significant differences were found in gpl60 antibody lev- 
els among patients grouped by partner index. 
Multivariate Analysis of Concordance 
Lymphocyte counts and viral load measures are highly 
correlated with each other and are associated with con- 
cordance (see Table 4). To evaluate the joint effect on 
the concordant status of the couples, the logarithm of 
CD4 counts, CDS counts, RNA copies, and p24 antibody 
titers were included in a multiple logistic regression 
model. Human immunodeficiency virus p24 antibody 
titers were not independently associated with concor- 
dance and were dropped from the model. Higher 
CD3+CD8+ counts were strongly associated with dis- 
cordance (the risk of concordance fell by 0.04 per log,, 
CD3+CDS+, P = 0.0001). Higher numbers of RNA copies 
were also associated with concordance (OR = 1.52 per 
power of 10, P = 0.03). The odds ratio for CD4 counts was 
2.54 (P = 0.03) a positive association with concordance. 
This apparent contradictory effect of CD4+ counts results 
from a strong association of CD3+CD8+ counts with dis- 
cordance at all levels of CD3+CD4+ counts, coupled with 
the high correlation between CD3+CD4+ and 
CD3+CD8+ counts. Thus when the effects are consid- 
ered jointly, CDS+ counts dominate the explanatory 
model and relegate CD4+ counts to an “adjustment fac- 
tor” (suppression in regression theory”). RNA copy num- 
ber was a significant factor in joint models, despite strong 
correlations with lymphocyte counts. These models indi- 
cate that CD3+CD8+ cells and viral load have distinct, 
independent effects on transmission. 
DISCUSSION 
The most striking finding in this large study was the 
increased numbers of CD3+CD8+ cells found in the index 
members of discordant couples as compared to either 
member in the concordant group. Differences in 
CD3+CD8+ levels persist after adjustment for stage of 
disease and CD3+CD4+ count. This increase in the num- 
ber of CD3+CD8+ cells was accompanied by a con- 
comitant decrease in the amount of viral activity 
measured by both HIV culture endpoint and quantitative 
plasma RNA. Although an inverse relation has been 
observed between the number of CD3+CDS+ cells and 
a reduced risk of progression from HIV infection to 
acquired immunodeficiency syndrome (AIDS) in some 
(but not all) studies, this is the first study to suggest the 
important role of CD3+CD8+ cells in reducing transmis- 
sion risk from the infected partner. 
The role of CDS+ lymphocytes in suppressing virus 
replication was first noted more than a decade ago.18 
Infection with HIV appears to elicit both noncytolytic 
and cytotoxic CDS+ responses, either of which is capa- 
ble of reducing the extent of viremia, thus affecting the 
course of the infection.19-23 Human immunodeficiency 
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virus suppressive activity of noncytolytic CDS+ cells 
appears to be due both to currently characterized 
chemokines and to chemokine-independent subsets.2*a25 
Multiple mechanisms may account for the 
CD3+CD8+ effects. First, as shown here and in other stud- 
ies, a robust CD3+CDS+ response appears to lower cir- 
culating viral burdens, and this may reduce transmission. 
Second, unrelated to circulating viral burdens, CD3+CDS+ 
cells or soluble products could control tissue HIV popu- 
lations and, thus, semen virus concentrations. Third, 
CD3+CDS+ cells or soluble products could in some way 
alter the virus in such a way as to reduce transmission 
likelihood, either by reducing pathogenic&y or by aug- 
menting host immune defenses. Although in all analyses 
the role of CD3+CD8+ cells appeared clearly predomi- 
nant, viral load also appeared to be an independent risk 
factor for transmission. The apparent secondary impor- 
tance of viral load in transmission (compared to 
CD3+CDS+ levels) suggests the need for reassessment of 
the notion that viral load is the critical variable in trans- 
mission likelihood. Case-control data are consistent with 
the findings of a recent maternal-infant transmission 
study in which viral load accounted for only a part of 
the transmission likelihood.26 
The p24 antibody levels appeared to be related 
(inversely) to viral load but did not appear to be an inde- 
pendent risk factor for concordance, whereas viral load 
did. The CD3+CDS+ differences between primary dis- 
cordants and primary concordants are impressive, but 
there are some obvious limitations to this study It is a 
case-control design, consequently, to impute causation 
to a risk factor (CD3+CDS+ differences) is precarious 
and must be advanced cautiously Additionally, there was 
no way to determine date of actual infection and, there- 
fore, duration of exposure of the second partner. Time 
since seroconversion was an unreliable indicator of expo- 
sure time, because many individuals were not serotested 
until the onset of AIDS symptoms. Adjustment for 
CD3+CD4+ count and stage of disease only partially cor- 
rects for lack of that information. For this analysis only ini- 
tial CD3+CDS+ and plasma RNA determinations were 
used; serial analyses could modify the conclusions. 
When this study was conducted, AZT was the over- 
whelming treatment option. Fewer than 10% of either 
concordant or discordant primary partners ever received 
any other antiviral therapy (i.e., dd1, ddC, or alpha-inter- 
feron). In fact, current antiviral therapy paralleled sub- 
jects’ clinical stage of disease: those on antiviral therapy 
had higher RNA levels and lower CDS counts than those 
not on therapy When comparisons are restricted to those 
on therapy, concordant primaries had higher RNA levels 
and lower CDS counts than discordant primaries; the 
same pattern was seen in concordant and discordant pri- 
mary partners not on therapy. Thus, the use of antiviral 
therapy does not explain the differences in CDS counts 
and RNA levels. 
Sperling et al recently published the results of a study 
of maternal-fetal transmission in which CD3+CDS+ lev- 
els did not appear to relate to likelihood of transmission.26 
Reasons for the differences between the present adult 
case-control study and their prospective maternal-infant 
study are not apparent, but could be due to other mater- 
nal-fetal immunologic changes associated with preg- 
nancy. Although the authors found no phenotypic 
differences (by syncytia formation) between isolates from 
discordant and concordant couples, there could be impor- 
tant strain differences, not reflected in syncytia forma- 
tion, that could determine transmission potential. 
In sum, the authors believe that this study supports 
the hypothesis that lack of transmission is, in significant 
part, determined by the CD3+CDS+ response of the 
infected partner. Elucidation of active antiviral products 
of CD3+CDS+ cells should further the understanding of 
CD3+CDS+-related lack of progression or transmission. 
The authors also have found human leukocyte antigen 
(HIA) allele differences between HIV-positive partners 
who transmit and those who do not. Although the HLA 
findings may be an unrelated phenomenon, they also 
could relate to genetic determinants of the CD3+CDS+ 
response. 27 The present study focused on the HIV-positive 
partner. A derivative multicenter study of highly exposed, 
still negative women, now in its final stages, indicates a 
CD3+CDS+ virus suppressive response in a substantial 
proportion of these women (Levy J. Personal communi- 
cation), strongly supporting the dominant CD3+CDS+ 
role for both infected and noninfected partners in reduc- 
ing transmission risk, a hypothesis also supported by the 
finding of CDS anti-HIV cytotoxic lymphocyte activity in 
highly exposed HIV-negative prostitutes.23 The apparent 
importance of CD3+CDS+ cells in reducing transmission 
likelihood obviously has major implications for evaluat- 
ing the potential usefulness of candidate HIV vaccines. 
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